not a pharmacist, just the tech side, but i’ve been seeing a lot of questions about the recent fda updates on compounded peptides. tbh fwiw, the new guidance is mostly about labeling and tracking, not a huge change for most of us. ime, the biggest impact will be on how pharmacies report their compounds, especially for glp-1s like tirzepatide. i’ve been working with these compounds for a while now, and i think the update is a step in the right direction for transparency. ❤️ the part that’s got me curious is how this will affect the availability of certain compounds, like retatrutide. anyone else have thoughts on this? i’ve been noticing some changes in how our pharmacy is handling the new regulations, and i’m wondering if others are seeing the same thing.
from a tracking perspective, the “availability” question has a downstream effect people miss. a change in pharmacy or formulation halfway through a run invalidates the comparison. you’re not logging the same intervention anymore, you’ve just started a new one without changing the label on your chart. 😂
hmm will “labeling” include the actual peptide purity and not just the mg?
the transparency goal is right, but framing this as “not a huge change for most of us” is the piece i’d push back on, especially for tirzepatide. with tirz officially off the fda shortage list, the entire legal justification for a 503a pharmacy to compound it from bulk substances just changed.
this isn’t a labeling or tracking update, it’s a fundamental shift in access and the legal ground pharmacies are standing on. the distinction between a 503a and 503b pharmacy, which is already a place where the regulatory framework on paper doesn’t always match the facility-specific inspection record, is about to matter a lot more.